By Kevin Penton ( May 27, 2015, 9:54 PM EDT) -- Acorda Therapeutics Inc. pushed back Tuesday against a challenge to its multiple sclerosis drug Ampyra by an organization with close ties to a hedge fund manager, telling the Patent Trial and Appeal Board that a patent for the medicine is valid....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.